Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
330.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
43
44
Next >
Want Rising Dividend Income? Buy Amgen Stock
August 10, 2023
The drugmaker possesses a solid medicine portfolio and pipeline.
Via
The Motley Fool
The 3 Best Biotech Stocks to Buy in August
August 09, 2023
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.
Via
InvestorPlace
Looking At Amgen's Recent Unusual Options Activity
August 09, 2023
Via
Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
August 08, 2023
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.
Via
InvestorPlace
Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading
August 08, 2023
Via
Investor Brand Network
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
August 08, 2023
Via
Benzinga
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
August 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
1 Top Dividend Growth Stock to Buy on the Dip
August 05, 2023
Investors' patience will be rewarded.
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
August 04, 2023
Via
Benzinga
Mind Science Targeting Big Brains and Portfolios
August 02, 2023
Via
AB Newswire
Is AbbVie Still a Good Dividend Stock to Buy?
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
August 07, 2023
Via
Benzinga
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
August 07, 2023
Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases.
Via
Benzinga
Is Growth Priced into Amgen Stock after Earnings Beat?
August 07, 2023
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock.
Via
MarketBeat
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
August 04, 2023
The pharmaceutical company has significantly enriched shareholders over the past 10 years.
Via
The Motley Fool
Looking At Amgen's Recent Unusual Options Activity
August 01, 2023
Via
Benzinga
Check Out What Whales Are Doing With AMGN
July 27, 2023
Via
Benzinga
Amgen Raises FY23 Outlook, Discloses Brief Readout From Tarlatamab Lung Cancer, Lumakras Colorectal Cancer Studies
August 04, 2023
Amgen Inc AMGN reported Q2 FY23 sales of $6.99 billion, up 7% Y/Y, beating the consensus of $6.63 billion.
Via
Benzinga
Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings
August 03, 2023
The massive biotech company also beat second-quarter expectations Thursday.
Via
Investor's Business Daily
Why Is Regeneron Pharmaceuticals Moving Higher Today?
August 03, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Stre
Via
Benzinga
3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years
August 03, 2023
Can these stocks keep the rate hikes coming?
Via
The Motley Fool
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
August 03, 2023
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.
Via
Benzinga
Amgen To Report Q2 Earnings: Here's What To Expect
July 31, 2023
Amgen will report second-quarter 2023 results on Aug. 3, after the market close.
Via
Talk Markets
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
July 31, 2023
Via
Benzinga
The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets
July 28, 2023
Via
Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
3 Things About Johnson & Johnson Every Smart Investor Knows
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
July 27, 2023
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
AbbVie Earnings, Revenue Fall Less Than Expected
July 27, 2023
Drug maker AbbVie reported Q2 profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.
Via
Investor's Business Daily
AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis
July 26, 2023
AbbVie Inc (NYSE: ABBV) announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab)...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.